Novartis Appealing Doan's Pills FTC $8 Mil. Corrective Ad Order
This article was originally published in The Tan Sheet
Executive Summary
Novartis plans to "file an appeal with a federal court" contesting the Federal Trade Commission's May 27 order requiring corrective advertising and labeling for Doan's Pills ad claims. In a 4-0 vote, the commission reversed a March 1998 administrative law judge's decision not to impose corrective advertising to remedy what FTC charges were deceptive superiority claims.